NCPC: Restructured Tetanus Vaccine (Escherichia coli) Clinical Trial Approved
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, NCPC announced that its subsidiary, North China Pharmaceutical Jintan Biotechnology Co., Ltd. (referred to as "Jintan Company"), has received the "Drug Clinical Trial Approval Notice" for the recombinant tetanus vaccine (Escherichia coli) approved by the National Medical Products Administration
According to the Zhitong Finance APP, NCPC (600812.SH) announced that its subsidiary, North China Pharmaceutical Jintan Biotechnology Co., Ltd. (referred to as "Jintan Company"), has received the "Drug Clinical Trial Approval Notice" for the recombinant tetanus vaccine (Escherichia coli) approved by the National Medical Products Administration